-
Mar 6, 2024
Stelo by Dexcom, the first glucose biosensor cleared by the FDA for over-the-counter use, will be available in the US for individuals aged 18 and older not using insulin therapy, making it accessible without a prescription. This small, wearable sensor, worn on the upper arm, will transmit glucose data directly to the user's smartphone. Developed by Dexcom, Stelo aims to empower people with Type 2 diabetes to manage their health effectively. Available from summer 2024 onwards, Stelo fills a crucial gap in the market, providing continuous glucose monitoring for those without insurance coverage or prescription access.
-
Feb 20, 2024
Modular Medical, Inc. has submitted its MODD1 next-generation insulin pump for FDA clearance, aiming to revolutionize the diabetes market with user-friendly and affordable technology. Chairman Paul DiPerna highlights the company's goal of encouraging wider adoption of insulin pumps by simplifying design and reducing costs.
-
Jan 22, 2024
The latest version of the CGM Certificate Program was built on our new learning platform. Enhancements range from more active engagement through interactive elements to more flexibility and accessibility.
-
Jan 12, 2024
Dexcom unveiled its new Stelo device during the J.P. Morgan Healthcare Conference. The Stelo is based on Dexcom's G7 CGM and is specifically designed for individuals who do not take insulin. This product is part of Dexcom's ongoing efforts to cater to a broader range of patients.
-
Dec 7, 2023
Tandem Diabetes Care, Inc. has announced the release of updated t:slim X2™ insulin pump software featuring integration with Dexcom G7 Continuous Glucose Monitoring (CGM) technology in the United States. The company plans to provide a complimentary remote software update to all in-warranty t:slim X2 users, allowing them to access Dexcom's latest CGM advancements. New t:slim X2 pumps with the integrated software are currently being shipped to customers, while the Dexcom G7 integration is expected to launch in additional countries outside the U.S. in early 2024.